Abingdon, UK, 10 December 2019 – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company developing population-based synthetic disease prophylaxis set-point vaccines in the field of infectious diseases, today announced the successful completion of preclinical testing of its lead vaccine candidate for Dengue Fever.
The vaccine construct, which comprises nature’s gene-chip peptides bound to a quantum cluster gold nanoparticle delivery system, was shown to have an excellent safety profile in a repeat dose GLP (Good Laboratory Practice) grade toxicology study using a standard industry model1. No adverse reactions were seen at any dose level. This completes Emergex’s preclinical data package, allowing movement into the clinical phases of development.
This work builds upon previous preclinical work including GLP toxicology testing of the gold nanoparticle, which will form the base for all of Emergex’s vaccines and efficacy studies of the vaccine candidate. In addition to providing disease prophylaxis to Dengue Fever, this vaccine candidate may also provide immunity to other flaviviruses including Zika and Yellow Fever, as the peptides chosen in the vaccine construct are highly conserved amongst flaviviruses.
Laurens Rademacher, Emergex’s Chief Technology Officer, commented: “This data highlights the progress we are making in developing our lead vaccine candidate. Now that we have completed preclinical testing, we have the necessary data to allow the initiation of our First in Man Phase I clinical trial. Our vision is to offer affordable, practical, safe and effective vaccine solutions. The success we are reporting today takes us closer to achieving this.”
Emergex is developing vaccines that reduce morbidity against existing and newly emerging infectious outbreaks for use by governments (National Health Services) and non-governmental organisations. It is also forming partnerships with pharmaceutical companies to generate both milestone and future royalty revenue streams on sales of vaccines.
Dengue Fever is a mosquito-borne viral infection prevalent in tropical and semi tropical parts of the world. In recent decades it has spread and today approximately half the world’s population is at risk of contracting it. Patients usually present with flu like symptoms, such as a headache and fever. However, Severe Dengue (Dengue Haemorrhagic Fever), can occur in up to 5% of cases and is a leading cause of hospitalisation and death among children in Dengue-affected regions2.
- Producing Nature’s Gene-Chips: The Generation of Peptides for Display by MHC Class I Molecules. Annu. Rev Immunol 2002.20:463-93.
- Health Organisation Facts about Dengue Fever – April 2019
– Ends –
Notes To Editors
About Emergex Vaccines Holdings Limited
Emergex Vaccines Holdings Limited, a UK-based biotechnology company headquartered in Abingdon, UK, is pioneering the development of ‘set-point’ vaccines to address some of the world’s most immediate health threats such as Dengue Fever, Zika, Ebola, pandemic flu and serious intra-cellular bacterial infections.
These set-point vaccines modify the initial immune status of recipients in a way that ‘primes’ their immune systems to recognise subsequent infectious agents much like a natural infection would do, preventing an acute or severe manifestation of the disease.
Emergex combines validated technologies together with the very latest scientific insights to develop its vaccines, including using synthetic peptide codes determined on actual infected cells and using a proprietary gold nanoparticle carrier system for programming.
The Company has a growing pipeline of vaccine candidates. The most advanced development programme is a vaccine for Dengue Fever, which may also be disease modifying for other Flaviviruses such as the Zika and Yellow Fever viruses. Emergex also has programmes in development for a universal Influenza vaccine and a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine and a Chikungunya vaccine.
Ashley Tapp / Genevieve Wilson
Phone: +44 (0)20 7457 2020